Svoboda | Graniru | BBC Russia | Golosameriki | Facebook
Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Novel Treatment Modalities of Type 1 Diabetes Mellitus: Opportunities and Challenges

Version 1 : Received: 3 June 2024 / Approved: 3 June 2024 / Online: 3 June 2024 (09:51:47 CEST)

How to cite: Salama, R. A. A.; Patni, M. M.; Ba-Hutair, S. N. M.; Wadid, N. A.; Akikwala, M. S. Novel Treatment Modalities of Type 1 Diabetes Mellitus: Opportunities and Challenges. Preprints 2024, 2024060058. https://doi.org/10.20944/preprints202406.0058.v1 Salama, R. A. A.; Patni, M. M.; Ba-Hutair, S. N. M.; Wadid, N. A.; Akikwala, M. S. Novel Treatment Modalities of Type 1 Diabetes Mellitus: Opportunities and Challenges. Preprints 2024, 2024060058. https://doi.org/10.20944/preprints202406.0058.v1

Abstract

Despite the effectiveness of insulin injections in managing hyperglycemia in Type 1 Diabetes, they fall short in addressing autoimmunity and regenerating damaged islets. This review aims to explore the potential of various treatment modalities for T1DM, including mesenchymal stem cells (MSCs), MSC-derived exosomes, gene therapy, islet allotransplantation, and pancreatic islet cell transplantation. Results: MSCs demonstrate efficacy in T1DM treatment through immunomodulation and tissue regeneration, although further research is warranted to optimize their therapeutic potential. Gene therapy presents a promising approach despite challenges such as donor shortage and immune rejection. Pancreatic islet cell transplantation emerges as a viable option, albeit with associated risks including graft rejection and the need for immunosuppression. Teplizumab, an FDA-approved humanized monoclonal antibody, revolutionizes the treatment landscape of Type 1 Diabetes by significantly delaying its onset, offering a paradigm shift since the discovery of insulin Conclusion: Ongoing studies and technological advancements in T1DM management offer a promising outlook for improved treatments and possibly even eradication on a global scale. MSCs, MSC-derived exosomes, gene therapy, and pancreatic islet transplantation hold considerable potential.

Keywords

type1 diabetes mellitus; mesenchymal stem cells; gene therapy; pancreatic islet cell transplantation; teplizumab

Subject

Medicine and Pharmacology, Medicine and Pharmacology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.